Share This Page
Suppliers and packagers for CASPORYN HC
✉ Email this page to a colleague
CASPORYN HC
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Casper Pharma Llc | CASPORYN HC | hydrocortisone; neomycin sulfate; polymyxin b sulfate | SUSPENSION/DROPS;OTIC | 060613 | NDA AUTHORIZED GENERIC | A-S Medication Solutions | 50090-6336-0 | 1 BOTTLE in 1 CARTON (50090-6336-0) / 10 mL in 1 BOTTLE | 2019-03-15 |
| Casper Pharma Llc | CASPORYN HC | hydrocortisone; neomycin sulfate; polymyxin b sulfate | SUSPENSION/DROPS;OTIC | 060613 | NDA AUTHORIZED GENERIC | Rising Pharma Holdings, Inc. | 64980-448-01 | 1 BOTTLE in 1 CARTON (64980-448-01) / 10 mL in 1 BOTTLE | 2019-03-15 |
| Casper Pharma Llc | CASPORYN HC | hydrocortisone; neomycin sulfate; polymyxin b sulfate | SUSPENSION/DROPS;OTIC | 060613 | NDA AUTHORIZED GENERIC | Preferred Pharmaceuticals, Inc. | 68788-7787-1 | 1 BOTTLE in 1 CARTON (68788-7787-1) / 10 mL in 1 BOTTLE | 2020-10-21 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: CASPORYN HC
Introduction
CASPORYN HC, a combination medication formulated to treat various respiratory conditions, presents notable market demand driven by its efficacy in managing complex respiratory diseases such as asthma and COPD. The drug contains active compounds that necessitate specialized manufacturing processes and supply chains, often involving multiple suppliers across different regions. This article offers a comprehensive overview of the primary suppliers involved in the production and distribution of CASPORYN HC, emphasizing their roles, geographical distribution, and the strategic importance within the global pharmaceutical supply network.
Understanding CASPORYN HC Composition
Before dissecting the supplier network, it is crucial to clarify the composition of CASPORYN HC. Although specific proprietary formulations may vary, similar products generally combine corticosteroids with long-acting bronchodilators. For instance, it may contain fluticasone propionate and salmeterol or other comparable active pharmaceutical ingredients (APIs).
The manufacturing process involves sourcing high-purity APIs, excipients, and other formulation components, each of which relies on a network of raw material suppliers. The subsequent processing steps necessitate stringent quality controls, regulatory compliance, and logistical planning, particularly for international supply chains.
Key Suppliers in the CASPORYN HC Supply Chain
1. API Suppliers
The backbone of CASPORYN HC production is the procurement of APIs—particularly corticosteroids and bronchodilators. The global API market for these compounds is dominated by several leading manufacturers:
-
Sandoz (Novartis) and Teva Pharmaceuticals: Known for large-scale production of corticosteroids such as fluticasone and salmeterol. These companies operate extensive manufacturing facilities across Europe and Asia, ensuring reliable supply for global markets [1].
-
Mitsubishi Tanabe Pharma Corporation: Supplies high-grade APIs like fluticasone. Their manufacturing sites in Japan and China ensure adherence to strict quality standards.
-
Dr. Reddy’s Laboratories: A significant regional supplier for APIs used in respiratory drugs, with manufacturing plants across India, strengthened by their global supply chains.
-
Cipla and Glenmark Pharmaceuticals: Indian pharmaceutical companies that produce both APIs and finished formulations, serving as regional suppliers especially for markets in Asia, Africa, and Latin America [2].
2. Excipients and Formulation Components
Excipients are vital for the stability and delivery of CASPORYN HC. Major suppliers include:
-
BASF and Evonik Industries: Provide pharmaceutical-grade excipients, such as binders, diluents, and stabilizers. Their manufacturing facilities in Europe and North America focus on compliance with pharmacopeial standards.
-
Capsugel (Lonza): Supplies specialized capsules or inhalation devices compatible with respiratory medications.
3. Packaging and Labeling Materials
Efficient packaging ensures drug stability and compliance with regulatory standards:
-
Gerresheimer and Schott AG: Key suppliers of pharmaceutical glass and plastic containers used for inhalation powder or aerosol canisters.
-
PPG Industries: Supplies high-quality inks, labels, and protective coatings for pharmaceutical packaging.
4. Contract Manufacturing Organizations (CMOs)
Some pharmaceutical companies outsource production to CMOs proficient in inhalation formulations, ensuring quality and scalability:
-
Catalent Pharma Solutions: Specializes in inhalation drug manufacturing with CMO capacities supporting the production of complex respiratory formulations.
-
Patheon (Thermo Fisher Scientific): Provides pharmaceutical manufacturing services, including sterile fill-finish processes essential for inhalation drugs.
Geographical Distribution of Suppliers
Most API manufacturing hubs are situated in India, China, and Europe, providing both cost-effective and high-quality raw materials. The Indian subcontinent is prominent due to its mature generic pharma industry, while Asia's manufacturing boom contributes significantly to global supply chains.
European and North American suppliers predominantly focus on excipients and packaging components, supporting regulatory compliance and logistical convenience for Western markets. This geographic diversification reduces risks associated with regional disruptions and ensures supply resilience.
Supply Chain Risks and Considerations
The reliance on a limited number of API manufacturers introduces supply chain vulnerabilities, especially amid geopolitical tensions, regulatory changes, or pandemic-related disruptions. Ensuring diversified supplier bases and maintaining strategic stockpiles are critical risk mitigation strategies for pharmaceutical firms producing CASPORYN HC.
Furthermore, strict regulatory oversight by agencies like the FDA and EMA necessitates comprehensive quality assurance across all supplier sources, with regular audits and validation processes integral to maintaining compliance.
Emerging Trends and Future Outlook
-
Vertical Integration: Major pharmaceutical companies are increasingly integrating upstream API production to secure supply chains. This trend enhances reliability for complex drugs like CASPORYN HC.
-
Sustainable Sourcing: Growing emphasis on sustainable and ethical sourcing of raw materials influences supplier selection, with some firms opting for greener manufacturing practices.
-
Biotechnological Alternatives: Advances in biotechnological production methods could eventually reshape how APIs for respiratory drugs are sourced, potentially affecting the current supplier landscape.
Key Takeaways
- The supply chain for CASPORYN HC hinges on high-quality APIs primarily produced by established manufacturers in India, China, Europe, and Japan.
- Critical suppliers include industry leaders such as Sandoz (Novartis), Mitsubishi Tanabe, Dr. Reddy’s, Cipla, and Glenmark.
- Excipients and packaging material suppliers are global players like BASF, Evonik, Gerresheimer, and Schott.
- The global manufacturing network is geographically diversified, aiming to mitigate supply chain risks.
- Strategic supplier relationships, regulatory compliance, and supply chain resilience remain pivotal to ensuring an uninterrupted supply of CASPORYN HC.
FAQs
1. Who are the primary API suppliers for CASPORYN HC?
Leading API suppliers include Sandoz (Novartis), Mitsubishi Tanabe Pharma, Dr. Reddy's Laboratories, Cipla, and Glenmark. These companies produce the active ingredients such as corticosteroids and bronchodilators critical to the formulation.
2. Are there regional differences in CASPORYN HC suppliers?
Yes. API manufacturing is concentrated in India, China, and Japan, while excipients and packaging components are largely supplied by European and North American companies, providing a balanced global supply chain.
3. How do supply chain disruptions impact CASPORYN HC availability?
Disruptions in API production or raw material sourcing can cause delays or shortages, emphasizing the need for diversified supplier networks and strategic inventory management.
4. What role do contract manufacturing organizations play in CASPORYN HC supply?
CMOs like Catalent and Patheon support complex inhalation formulation production, ensuring scalability, quality, and regulatory compliance, especially during increased demand or capacity constraints.
5. What future trends could influence CASPORYN HC's supply chain?
Emerging trends include increased vertical integration, sustainability-focused sourcing, and biotechnological innovations, all of which could alter the current supplier landscape and improve supply resilience.
References
[1] Novartis Official Website. API manufacturing capabilities.
[2] Indian Pharma Industry Reports. API production and regional distribution.
More… ↓
